Riskpilot← Back to searchSign inGet full accessPHARMADVICE ApS
APSActiveCVR 26527651Generatorvej 8C, 1. tvAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20028 employees
Revenue 2024
DKK 6,7M
+13% vs 2023
EBITDA margin
12.8%
+6% vs 2023
Equity ratio
70.2%
Financial strength
Net profit 2024
DKK 659K
+8% vs 2023
| Revenue | DKK 6,7M | +13% |
| EBITDA | DKK 859K | +6% |
| Net profit | DKK 659K | +8% |
| Total assets | DKK 2,1M | -5% |
| Equity | DKK 1,5M | +4% |
| Employees | 8 | — |
Legal name
PHARMADVICE ApS
CVR number
26527651
Legal form
Anpartsselskab
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
21. marts 2002
Share capital
DKK 125.000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed inden for handel og industri og anden i forbindelse hermed stående virksomhed, primært rådgivning indenfor medicinalbranchen.
Address
Generatorvej 8C, 1. tv
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.411 | 5.414 | 4.033 | 4.483 | 5.918 | 4.614 | 3.841 | 4.553 | 4.205 | 3.928 | 5.312 | 5.940 | 6.719 |
| Staff expenses | -3.357 | -5.269 | -4.054 | -4.210 | -4.738 | -4.649 | -3.876 | -4.564 | -3.790 | -3.547 | -4.365 | -5.132 | -5.860 |
| EBITDA | 54 | 145 | -21 | 272 | 1.180 | -35 | -35 | -10 | 415 | 380 | 946 | 808 | 859 |
| Depreciation & amort. | -51 | -11 | -11 | -19 | -30 | -35 | -32 | -20 | -11 | -15 | -15 | -12 | -0 |
| EBIT | 3 | 134 | -32 | 254 | 1.150 | -70 | -67 | -30 | 404 | 366 | 931 | 795 | 859 |
| Net financials | -0 | -0 | -6 | 2 | 1 | -8 | -3 | -5 | -8 | -11 | -10 | -15 | -14 |
| Profit before tax | 3 | 133 | -38 | 255 | 1.151 | -79 | -70 | -35 | 396 | 355 | 921 | 780 | 845 |
| Tax | 4 | 39 | -6 | 60 | 255 | -16 | -15 | -7 | -0 | 79 | 204 | 172 | 186 |
| Net profit | -1 | 94 | -32 | 196 | 896 | -62 | -55 | -28 | 309 | 276 | 717 | 609 | 659 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.239 | 2.611 | 1.838 | 2.194 | 3.297 | 1.776 | 1.668 | 1.991 | 2.480 | 1.625 | 2.285 | 2.242 | 2.135 |
| Equity | 1.182 | 1.180 | 1.050 | 1.145 | 1.907 | 948 | 832 | 704 | 1.013 | 839 | 1.531 | 1.440 | 1.499 |
| Long-term debt | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 175 | 0 | 0 | 0 | 17 | 0 |
| Short-term debt | 1.057 | 1.426 | 789 | 1.027 | 1.376 | 828 | 835 | 1.112 | 1.467 | 786 | 753 | 785 | 637 |
| Total debt | 1.057 | 1.426 | 789 | 1.027 | 1.376 | 828 | 835 | 1.287 | 1.467 | 786 | 753 | 802 | 637 |
EBITDA margin
12.8%
This company
15.8%
Market median
-19% vs market
20122024
Equity ratio
70.2%
This company
38.2%
Market median
+84% vs market
20122024
Return on equity
44.0%
This company
18.4%
Market median
+139% vs market
20122024
Net profit margin
9.8%
This company
8.1%
Market median
+21% vs market
20122024
Asset turnover
3.15×
This company
1.12×
Market median
+181% vs market
20122024
Debt / equity
0.42×
This company
0.62×
Market median
+32% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SØ Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
KS Management | Management | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2002 | — | — | |
| Chairman | 2002 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Felumb Holding ApS | Company | 100.0% | 100.0% | 2021 |
Frederiksstaden Pharma ApS | Company | 100.0% | 100.0% | 2020 |
| Individual | 66.7% | 66.7% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Felumb Holding ApS
PHARMADVICE ApS Board members of PHARMADVICE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Susanne Ølsgaard Felumb | Chief Executive Officer | 0 companies |
| Klaus Søgaard | Management | 0 companies |
| Troels Elkiær Andersen | Board of Directors | 0 companies |
| Jan-Erik Gunnar Svensson | Chairman | 0 companies |